8 January 2026
VBB advises Adjuvant Global Health Technologies on investment in Phoenix Biosciences
1 min read
VBB has advised private investment fund Adjuvant Global Health Technologies (Adjuvant) on its investment in Phoenix Biosciences.
In the context of the Belgian pre-pack bankruptcy procedure relating to the distressed Univercells group, new corporate vehicle Phoenix Biosciences has acquired certain assets of Univercells subsidiary Quantoom Biosciences, a full-stack RNA partner for mRNA- and saRNA-based vaccines and therapeutics.
Adjuvant was a shareholder in the Univercells group and, alongside fellow shareholders, has contributed to a capital raise for Phoenix Biosciences.
The VBB team comprised partner Caroline DAOUT, counsel Virginie Lescot and associate Jens Westerwoudt.
->
News & insights
1 min
read
read
Briefings
VBB secures lowest anti-dumping duty for Hankook in EU passenger car tyre investigation
7 July 2026
2 min
read
read
Briefings
Lithuanian Competition Authority Fines Pharmacy Association and Individual Firms for Collusion while Participating in Margin-setting Procedure
14 December 2022
2 min
read
read
Briefings
France - Supreme Court Allows Follow-on Damages Action by Health Insurer in Wake of Sanofi’s Denigration Strategy against Generic Rivals
13 October 2023
2 min
read
read
Briefings
European Commission Sends Statement of Objections to Teva over Abusive Patent Filings and Disparagement of Generic Competitors
11 October 2022
1 min
read
read
Briefings
F. Hoffmann-La Roche and Novartis (Avastin - Lucentis) – ECJ Finds Concerted Efforts to Restrict Off-label Use of Medicinal Products Likely to Breach Competition Rules
24 January 2018
3 min
read
read
Briefings
Advocate General Recommends to Court of Justice of European Union to Allow Reimbursement of Off Label Use of Medicine for Purely Budgetary Reasons
30 August 2018
3 min
read
read
Briefings
“National Healthcare Insurance Systems Are Allowed To Reimburse Off-Label Use of Medicine” Says ECJ
21 November 2018
3 min
read
read
Briefings
French Competition Authority - Genentech, Novartis and Roche Fined EUR 444 million in Saga Involving Wet Age-Related Macular Degeneration
9 September 2020
